Literature DB >> 17589956

Predicting prognosis of rectal cancer patients with total mesorectal excision using molecular markers.

Jun-Jie Peng1, San-Jun Cai, Hong-Feng Lu, Guo-Xiang Cai, Peng Lian, Zu-Qing Guan, Ming-He Wang, Ye Xu.   

Abstract

AIM: To explore the prognostic variables in rectal cancer patients undergoing curative total mesorectal excision and the effect of postoperative chemotherapy in advanced rectal cancer.
METHODS: A total of 259 consecutive rectal cancer patients treated with curative total mesorectal excision between 1999 and 2004 were collected. p53, p21, PCNA, and CD44v6 were examined using immunohistochemistry (IHC). The correlation between clinicopathological or molecular variables and clinical outcomes, including local recurrence, metastasis, disease-free survival and overall survival, was analyzed.
RESULTS: The median follow-up was 44 mo. Five-year survival rates and 5-year disease free survival rates were 75.43% and 70.32%, respectively. Multi-analysis revealed TNM staging, preoperative CEA, and CD44v6 level were independent risk factors predicting overall survival or disease free survival. The hazard ratio of peroperative CEA was 2.65 (95% CI 1.4-5) and 3.10 (95% CI 1.37-6.54) for disease free survival and overall survival, respectively. The hazard ratio of CD44v6 was 1.93 (95% CI 1.04-3.61) and 2.21 (95% CI 1.01-4.88) for disease free survival and overall survival, respectively. TNM staging was the only risk factor predicting local recurrence. Postoperative chemotherapy without radiotherapy did not improve patients' outcome.
CONCLUSION: TNM staging, preoperative CEA and CD44v6 were independent prognostic factors for rectal cancer patients with total mesorectal excision. Postoperative chemotherapy may be only used together with radiotherapy for rectal cancer patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17589956      PMCID: PMC4171158          DOI: 10.3748/wjg.v13.i21.3009

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  19 in total

1.  A new rapid immunohistochemical staining technique using the EnVision antibody complex.

Authors:  U Kämmerer; M Kapp; A M Gassel; T Richter; C Tank; J Dietl; P Ruck
Journal:  J Histochem Cytochem       Date:  2001-05       Impact factor: 2.479

2.  Chemotherapy with preoperative radiotherapy in rectal cancer.

Authors:  Jean-François Bosset; Laurence Collette; Gilles Calais; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Alain Daban; Etienne Bardet; Alexander Beny; Jean-Claude Ollier
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

3.  Immunohistochemical expression of the CD44 variant 6 in colorectal adenocarcinoma.

Authors:  T Ishida
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

4.  [A comparative study on the prognostic value of the nuclear expression of protein p53 vis-à-vis histopathology in colorectal cancer].

Authors:  M Díez; J Camuñas; J M Enríquez; A González; E Torabuela; A Gutiérrez; T Ratia; J M Mugüerza; A Martín; A Ruiz; J Granell
Journal:  An Med Interna       Date:  1996-05

5.  Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer.

Authors:  Yong-Jun Liu; Pei-Song Yan; Jun Li; Jing-Fen Jia
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

6.  p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis.

Authors:  A Paradiso; M Rabinovich; C Vallejo; M Machiavelli; A Romero; J Perez; J Lacava; M A Cuevas; R Rodriquez; B Leone; M G Sapia; G Simone; M De Lena
Journal:  Int J Cancer       Date:  1996-12-20       Impact factor: 7.396

7.  Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997.

Authors:  R J Heald; B J Moran; R D Ryall; R Sexton; J K MacFarlane
Journal:  Arch Surg       Date:  1998-08

8.  Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients.

Authors:  A Yamaguchi; T Urano; T Goi; M Saito; K Takeuchi; K Hirose; G Nakagawara; H Shiku; K Furukawa
Journal:  J Clin Oncol       Date:  1996-04       Impact factor: 44.544

9.  Total mesorectal excision in the operative treatment of carcinoma of the rectum.

Authors:  W E Enker; H T Thaler; M L Cranor; T Polyak
Journal:  J Am Coll Surg       Date:  1995-10       Impact factor: 6.113

10.  CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor.

Authors:  R Stauder; W Eisterer; J Thaler; U Günthert
Journal:  Blood       Date:  1995-05-15       Impact factor: 22.113

View more
  10 in total

1.  Preoperative carcinoembryonic antigen and prognosis of colorectal cancer. An independent prognostic factor still reliable.

Authors:  Giovanni Li Destri; Antonio Salvatore Rubino; Rosalia Latino; Fabio Giannone; Raffaele Lanteri; Beniamino Scilletta; Antonio Di Cataldo
Journal:  Int Surg       Date:  2015-04

2.  Down-regulation of miR-126 expression in colorectal cancer and its clinical significance.

Authors:  Xiang-Min Li; Ai-Min Wang; Juan Zhang; Hong Yi
Journal:  Med Oncol       Date:  2010-07-31       Impact factor: 3.064

3.  Prognostic significance of response to preoperative radiotherapy, lymph node metastasis, and CEA level in patients undergoing total mesorectal excision of rectal cancer.

Authors:  Soichiro Ishihara; Toshiaki Watanabe; Tomomichi Kiyomatsu; Koji Yasuda; Hirokazu Nagawa
Journal:  Int J Colorectal Dis       Date:  2010-09-01       Impact factor: 2.571

4.  Down-regulation of miR-31 expression in gastric cancer tissues and its clinical significance.

Authors:  Yuanyuan Zhang; Junming Guo; Dong Li; Bingxiu Xiao; Ying Miao; Zhen Jiang; Hui Zhuo
Journal:  Med Oncol       Date:  2009-07-14       Impact factor: 3.064

5.  Colorectal cancer: prognostic values.

Authors:  Suzana Manxhuka-Kerliu; Skender Telaku; Halil Ahmetaj; Arijeta Baruti; Sadushe Loxha; Agron Kerliu
Journal:  Bosn J Basic Med Sci       Date:  2009-02       Impact factor: 3.363

6.  Lack of CD44 variant 6 expression in rectal cancer invasive front associates with early recurrence.

Authors:  Suvi Tuulia Avoranta; Eija Annika Korkeila; Kari Juhani Syrjänen; Seppo Olavi Pyrhönen; Jari Toivo Tapio Sundström
Journal:  World J Gastroenterol       Date:  2012-09-07       Impact factor: 5.742

7.  Increased expression of miR-421 in human gastric carcinoma and its clinical association.

Authors:  Zhen Jiang; Junming Guo; Bingxiu Xiao; Ying Miao; Rong Huang; Dong Li; Yuanyuan Zhang
Journal:  J Gastroenterol       Date:  2009-10-03       Impact factor: 7.527

Review 8.  The prognostic value of the apoptosis pathway in colorectal cancer: a review of the literature on biomarkers identified by immunohistochemistry.

Authors:  Eliane C M Zeestraten; Anne Benard; Marlies S Reimers; Philip C Schouten; Gerrit J Liefers; Cornelis J H van de Velde; Peter J K Kuppen
Journal:  Biomark Cancer       Date:  2013-07-04

9.  Detection of Cancer Stem Cells in Colorectal Cancer: Histopathological and Immunohistochemical Study.

Authors:  Nour El Hoda S Ismaiel; Walid M Sharaf; Dina O Helmy; Mona M Zaki; Manal A Badawi; Ahmed S A Soliman
Journal:  Open Access Maced J Med Sci       Date:  2016-12-07

10.  CD44v6 overexpression related to metastasis and poor prognosis of colorectal cancer: A meta-analysis.

Authors:  Ji-Lin Wang; Wen-Yu Su; Yan-Wei Lin; Hua Xiong; Ying-Xuan Chen; Jie Xu; Jing-Yuan Fang
Journal:  Oncotarget       Date:  2017-02-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.